Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Schedule of Cumulative Effect of Changes to Condensed Consolidated Balance Sheet for Adoption of ASC 606

The cumulative effect of changes made to the Condensed Consolidated Balance Sheet at January 1, 2018 for the adoption of ASC 606 were as follows (in thousands):

	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Assets:
Accounts receivable	$	19,967		$	17,243	$	37,210
Prepaid expenses and other current assets		9,118			710		9,828
Other assets		1,760			573		2,333
	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Liabilities:
Deferred revenue	$	2,212		$	156	$	2,368
Roche related-party deferred revenue		3,742			78		3,820
	Balance at December 31, 2017			Adjustments Due to ASC 606		Balance at January 1, 2018
Equity:
Accumulated deficit	$	(506,349	)	$	18,292	$	(488,057	)

Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet

In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on our Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet was as follows (in thousands):

	For the three months ended June 30, 2018
Revenue:	As  Reported Under ASC 606		Effect of Change Higher/(Lower)		Balances Without Adoption of ASC 606
Molecular information services	$	38,702	$	1,890	$	40,592
Related-party molecular information services from Roche		12,005		1,995		14,000
Pharma research and development services		3,732		4,050		7,782
Related-party pharma research and development services from Roche		2,567		—		2,567
	For the six months ended June 30, 2018
Revenue:	As  Reported Under ASC 606		Effect of Change Higher/(Lower)		Balances Without Adoption of ASC 606
Molecular information services	$	70,478	$	5,102	$	75,580
Related-party molecular information services from Roche		26,820		1,620		28,440
Pharma research and development services		8,514		128		8,642
Related-party pharma research and development services from Roche		4,034		—		4,034

	June 30, 2018
Assets:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Accounts receivable	$	40,939		$	(12,077	)	$	28,862
Prepaid expenses and other current assets		5,641			(177	)		5,464
Other assets		3,142			(357	)		2,785
Liabilities:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Deferred revenue	$	10,720		$	(136	)	$	10,584
Roche related-party deferred revenue		8,190			(1,259	)		6,931
Equity:	As  Reported Under ASC 606			Effect of Change Higher/(Lower)			Balances Without Adoption of ASC 606
Accumulated deficit	$	(558,851	)	$	(11,216	)	$	(570,067	)